Jiangsu Nhwa Secures Exclusive Rights to Teva’s Austedo in China with $30 Million Deal
Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262), based in China, has entered into a cooperation...
Guangdong Province Releases New Batch of Urgently Needed Drugs and Medical Devices for Greater Bay Area
The Medical Products Administration and Health Commission of Guangdong province have released the sixth batch...
Tencent Hands Over Two Former CSIG Employees to Authorities on Embezzlement Allegations
Chinese internet conglomerate Tencent has announced via its anti-fraud department’s official channel that former employees...
Sanofi’s Dupixent Receives FDA Priority Review for COPD Indication Extension
Sanofi (NASDAQ: SNY), a French multinational pharmaceutical company, announced last week that the US Food...
Kexing Pharmaceutical Partners with Yabao to Distribute Generic Nexavar in Ten Countries
China-based Kexing Pharmaceutical (SHA: 688136) has entered into an overseas cooperation agreement with fellow domestic...
Fujian Province Issues Provisional Regulations for Managing Medical Representative Visits
The Fujian provincial health commission and medical products administration have jointly issued the “Provisional Regulations...
GenScript’s Subsidiary Legend Biotech Gets CHMP Nod for Carvykti Label Expansion in Multiple Myeloma
GenScript Biotech Corporation (HKG: 1548), a China-based Contract Research Organization (CRO), has announced that its...
Celltrion’s Infliximab Biosimilar Shows Promising Long-Term Efficacy and Safety in CD and UC
South Korean biopharmaceutical company Celltrion (KRX: 068270) has presented positive long-term efficacy and safety data...
Takeda’s Recombinant Pig FVIII Drug for Acquired Hemophilia A Approved in China
The National Medical Products Administration (NMPA) website has indicated that Takeda (TYO: 4502)’s Obizur (susoctocog...
Mabwell Bioscience Cancels Licensing Agreements with Yangtze River Pharma for Two Drug Candidates
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...
Mabwell Bioscience’s Nectin-4 Targeting ADC Earns FDA Fast-Track Designation for Esophageal Cancer
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...
Boehringer-Ingelheim Partners with CBmed to Accelerate First-in-Class Cancer Medicines Development
Boehringer-Ingelheim, a German pharmaceutical giant, has entered into a long-term strategic partnership with Austria-based CBmed...
Polpharma Biologics’ Biosimilar Candidate PB016 Shows Comparable Profiles to Takeda’s Entyvio
Polish biotechnology firm Polpharma Biologics has announced positive results from a comparability study for its...
Jiangsu Hengrui Receives NMPA Approval for Adjuvant Therapy Clinical Study of Adebrelimab in NSCLC
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a prominent Chinese pharmaceutical company, has received approval...
BioCity Biopharma Achieves Full Enrollment in Phase II Study of SC0062 for IgA Nephropathy
BioCity Biopharma, a Chinese biotechnology company, has announced the completion of enrollment for all 120...
Livzon Pharmaceutical Gets CDE Green Light for JP-1366 Reflux Esophagitis Clinical Study
Livzon Pharmaceutical Group Inc. (HKG: 1513), a leading Chinese pharmaceutical company, has announced that its...
Hinova Pharmaceuticals’ HP537 Receives CDE Approval for Clinical Study in Hematologic Malignancies
Hinova Pharmaceuticals Inc. (SHA: 688302), a biotech company based in Chengdu, has announced that it...
Jiangsu Hengrui’s CD79b Targeting ADC SHR-A1912 Earns FDA Fast-Track Designation for R/R DLBCL
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has announced that...
Rossum Robot’s Intelligent Surgical Robot for Trauma and Spinal Surgery Clears NMPA Approval
Rossum Robot, a Beijing-based developer of orthopedic surgical robots specializing in pelvic fracture procedures, has...
AstraZeneca’s Tagrisso Meets PFS Endpoint in Late-Stage NSCLC Trial and Expands FDA Approval
AstraZeneca (AZ; NASDAQ: AZN), a leading UK-based pharmaceutical company, has announced that a late-stage trial...